C9orf72 ALS study finds little difference in cognition or behaviour, except visuospatial skills
Mainly of interest to researchers studying genotype–phenotype relationships and cognitive outcomes
Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.
Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.
Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.
Sponsors
The most common genetic cause of ALS/MND, and also of frontotemporal changes. Every Feed story mentioning it, newest first.
Showing 51 of 943 stories
Mainly of interest to researchers studying genotype–phenotype relationships and cognitive outcomes
· 2 days ago
Mainly of interest to researchers studying nucleolar stress, C9orf72-linked ALS/FTD and neurodegeneration.
· 5 days ago
Relevant to researchers studying genotype-linked cognitive and affective theory-of-mind impairment
· 6 days ago
Provides validated C9orf72 patient-derived iPSC lines for disease-mechanism studies.
· 8 days ago
Provides replicated donor-level lncRNA findings and methodological insights for ALS neurobiology research
· 9 days ago
Important for researchers studying nucleolar integrity, arginine-rich dipeptide repeats and C9orf72-linked neurodegeneration.
· 23 days ago
Directly informs microglial phagocytosis, autophagy, lysosomal pathways, and C9orf72 versus sporadic disease models.
· 24 days ago
Mainly of interest to researchers studying MND genetics, testing patterns, and population variation.
· 25 days ago
Important for researchers studying glial toxicity, DPRs, ERV activation and C9orf72 disease models
· 25 days ago
Relevant to researchers studying C9orf72, proteostasis and neurodegenerative disease mechanisms.
· 25 days ago
Provides mechanistic evidence linking RNA-exosome surveillance and EXOSC3 to RAN translation and DPR production.
· 26 days ago
Directly informs proteomic signatures, genetic subgroup biology and diagnostic panel development.
· 27 days ago
Mainly of interest to researchers studying MND genetics and regional variation
· 1 month ago
Mainly of interest to researchers studying ALS genetics and diagnostic yield
· 1 month ago
Important for researchers studying synaptic dysfunction, cryptic transcripts, and C9ORF72 mechanisms.
· 1 month ago
Mainly of interest to researchers studying PF4, OPTN-dependent autophagy and SOD1 pathology
· 1 month ago
Important for researchers studying RAN translation and neuron-specific translational regulation
· 1 month ago
Relevant to researchers studying protein pathology, transgenic models, and translational ALS methods.
· 1 month ago
Provides single-cell evidence linking neuronal vulnerability to cellular respiration and ATP synthesis.
· 2 months ago
Directly relevant to researchers studying C9orf72 biology, transcriptomics and subtype-specific mechanisms.
· 2 months ago
Provides a new animal model linking repeat expression, C9orf72 loss, spinal pathology, and motor dysfunction.
· 2 months ago
Important for researchers studying RAN translation as a pathogenic mechanism and therapeutic target.
· 3 months ago
Maps research trends, immune targets, collaboration networks, and translational priorities.
· 3 months ago
Provides mechanistic and preclinical evidence linking poly(GR), the integrated stress response and ATXN2
· 4 months ago
Relevant to clinicians assessing dropped head syndrome and olanzapine-associated cervical dystonia in the FTD-ALS spectrum.
· 4 months ago
Mainly of interest to researchers studying C9orf72 mechanisms, guide-RNA screening and genome-editing safety.
· 4 months ago
Provides a CRISPR knock-in model and proteomic data for studying polyGA pathology
· 6 months ago
Important for researchers studying TYK2, cryptic exons and TDP-43-associated neuroinflammation
· 6 months ago
Mainly of interest to researchers following genetics, biomarkers, models and early-career research developments.
· 6 months ago
Identifies a gene–microbe interaction and bacterial glycogen pathway for further investigation
· 6 months ago
Provides a new CNS-targeted mouse model linking C9orf72 repeats, pathology, and motor dysfunction.
· 7 months ago
Covers current findings across biomarkers, mechanisms, trials, genetics and translational research
· 7 months ago
Mainly of interest to researchers studying penetrance and genetic modifiers of C9orf72 disease.
· 9 months ago
Important for researchers studying stage-specific neuroimaging biomarkers and disease trajectories.
· 9 months ago
Directly informs epigenetic mechanisms and experimental targets in C9orf72 ALS/FTD.
· 11 months ago
Provides mechanistic evidence on glial toxicity, DPRs, ERV activation, and non-cell-autonomous effects.
· 11 months ago
Mainly of interest to researchers studying C9orf72 phenotypes and the ALS-FTD spectrum.
· 11 months ago
Directly relevant to researchers studying glial mechanisms, genetic pathways and therapeutic targets
· March 2025
Relevant to clinicians monitoring upcoming efficacy and safety evidence
· March 2025
Provides a sensitive assay and structural insights for studying GC-rich C9ORF72 repeat RNA.
· February 2025
Mainly of interest to researchers studying genomic drug repurposing and C9orf72 disease biology.
· October 2024
Provides a detailed amplification-free sequencing method for accurately measuring large C9orf72 expansions.
· September 2024
Relevant to researchers studying C9orf72 biology, disease models and therapeutic approaches
· August 2024
Provides genetic, autonomic, neuroimaging and biomarker findings across the C9orf72 disease spectrum.
· July 2024
Offers mechanistic data linking C9orf72 to SEC16A, COPII transport and lipid metabolism.
· May 2024
Directly informs research on glucose metabolism, RAN translation, DPR toxicity and C9orf72 ALS/FTD models.
· April 2024
Mainly of interest to researchers following oligogenicity and genomics work
· March 2024
Provides a detailed patient-derived iPSC protocol for studying C9ORF72 repeat-expansion ALS.
· January 2024
Mainly of interest to researchers studying genetic overlap and variants across neurodegenerative diseases.
· January 2024
Directly informs repeat-length effects, animal models, molecular pathology and early biomarker development.
· February 2021
Mainly of interest to researchers studying RAN proteins, antibody delivery and C9orf72 disease models.
· December 2019
Sponsors